Core Insights - Neuronetics Inc. shares increased by 41.08% to $2.06 in after-hours trading following preliminary fourth-quarter 2025 financial results [1] Financial Performance - The company reported fourth-quarter 2025 revenue of $41.8 million, representing a 23% increase on an adjusted pro forma basis and an 86% increase compared to fourth-quarter 2024 on an as-reported basis [2] - Revenue from the NeuroStar system was $18.3 million, up 9% pro forma, while clinic revenue reached $23.5 million, up 37% pro forma [2] - Full-year 2025 revenue totaled $149.2 million, up 15% on an adjusted pro forma basis [4] - Neuronetics ended 2025 with $34.1 million in total cash, including cash equivalents and restricted cash [4] Operational Highlights - The company shipped 49 NeuroStar Advanced Therapy systems and generated positive operating cash flow of $0.9 million during the quarter, consistent with previously issued guidance [3] - CEO Keith Sullivan emphasized the translation of strong revenue performance into positive operating cash flow during the quarter [4] Market Metrics - Neuronetics has a market capitalization of $99.99 million, with a 52-week high of $5.91 and a 52-week low of $1.25 [5] - The stock has declined by 62.85% over the past 12 months, closing at $1.46, down 2.01% [5]